---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-104567"
form_type: "8-K"
ticker: "HOTH"
cik: "0001711786"
company_name: "Hoth Therapeutics, Inc."
filed_at: "2024-12-02T23:59:59+00:00"
generated_at: "2026-05-29T11:26:36.546144+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Hoth Therapeutics releases December 2024 corporate presentation highlighting pipeline and milestones

## Summary
- HT-001 Phase 2a for EGFR inhibitor skin toxicity: all sites active, enrolling open-label and double-blind; interim PK data expected Q1 2025.
- HT-KIT: pre-IND meeting with FDA successful; IND-enabling tox studies ongoing; IND submission target Q4 2025.
- HT-ALZ: US patent awarded Q3 2024; preclinical studies completed at WashU; pre-IND meeting planned for 2025.
- BioLexa Phase 1b data readout completed in 2023; proof-of-concept results shown; non-corticosteroid treatment for atopic dermatitis.
- 7.7M shares outstanding as of Nov 29, 2024; cash on hand sufficient to fund current clinical and preclinical programs.

## SEC filing metadata
- accession: 0001213900-24-104567
- form_type: 8-K
- ticker: HOTH
- cik: 0001711786
- company_name: Hoth Therapeutics, Inc.
- filed_at: 2024-12-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711786/000121390024104567/0001213900-24-104567-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711786/000121390024104567/ea0223333-8k_hoth.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-104567
- JSON: https://secwatch.observer/filing/0001213900-24-104567.json
- Plain text: https://secwatch.observer/filing/0001213900-24-104567.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.